Yeungnam Univ J Med.
2021 Jan;38(1):65-69. 10.12701/yujm.2020.00269.
Development of donepezil-induced hypokalemia following treatment of cognitive impairment
- Affiliations
-
- 1Division of Nephrology, Department of Internal Medicine, Incheon St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea
- 2Division of Nephrology, Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, The Catholic University of Korea, Seoul, Korea
- KMID: 2512069
- DOI: http://doi.org/10.12701/yujm.2020.00269
Abstract
- Donepezil is a cholinesterase inhibitor used extensively to treat Alzheimer disease. The increased cholinergic activity is associated with adverse effects, therefore gastrointestinal symptoms, including nausea, vomiting, and diarrhea, are common. Hypokalemia is a rare adverse event that occurs in less than 1% of donepezil-treated patients. Although hypokalemia of mild and moderate grade does not present serious signs and symptoms, severe hypokalemia often results in prolonged hospitalization and mortality. Herein, we report a case of hypokalemia developed after the initiation of donepezil therapy for cognitive impairment.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Cognitive Enhancing Activity of Cynaroside Isolated from Lysimachia christinae on Memory Impairment Insulted by Scopolamine
- Effect of Glycyrrhizic Acid on Scopolamine-Induced Cognitive Impairment in Mice
- The Effects of Donepezil, an Acetylcholinesterase Inhibitor, on Impaired Learning and Memory in Rodents
- Improvement of Visuo-spatial Function Assessed by Raven’s Colored Progressive Matrices in Dementia with Lewy Bodies by Donepezil Treatment
- The Change of K-MMSE Following Donepezil Medication in Patients with Alzheimer's Disease and Small Vessel Dementia, and the Characteristics of Alzheimer's Disease with Meaningful K-MMSE Change
